IRCCS CROB - CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA

Altri Lavori Scientifici

1. Stefania Meschini (a), Maria Condello (a), Annarica Calcabrini (a), Manuela Marra (a), Giuseppe Formisano (a), Pasquale Lista (c), Elena Federici (b), Giuseppe Arancia (a) la voacamina: alcaloide vegetale con attivita' citotossica e chemiosensibilizzante in cellule tumorali in vitro
(a) Dipartimento di Tecnologie e Salute, Istituto Superiore di Sanità, Roma;
(b) Dipartimento del Farmaco, Istituto Superiore di Sanità, Roma;
(c) Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture (PZ).
Source: Rapporti ISTISAN 08/41


2. . Villani O, Guariglia R, Pietrantuono G, Martorelli MC, D'Auria F, Zupa A, Bianchino G, Improta G, Colaizzo D, Musto P. Anagrelide as a therapeutic option for reducing platelet count in patients with refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T). New Horizons in Haematology. Berlin 2008.

3. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Volin L, Musto P, Bosi A, Corradini P, Goldschmidt H, Morris C, Gahrton G on behalf of the EBMT CLWP Multiple Myeloma Subcommitee. Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously intreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT. 34th EBMT Annual Meeting, Florence, Mar 30-Apr 2, 2008 (Bone Marrow Transplantation 2008, 41(s1)).

4. Mele A, Rana A, De Francesco R, Del Casale C, Messa A, Sibilla S, Milone G, Olivieri A, Mettivier V, Pezzullo L, Iacopino P, Scalzulli P, Musto P, Ostuni A, Pavone V. Radioimmunotherapy with haematopoietic stem cell transplantation for treatment of malignant non-Hodgkin lymphoma: multicentre study on thirty patients. 34th EBMT Annual Meeting, Florence, Mar 30-Apr 2, 2008 (Bone Marrow Transplantation 2008, 41(s1)).

5. Ria R, Musto P, Barletta MA, Guariglia R, Iodice G, Vacca A, Dammacco F. 90Y ibritumomab tiuxetan for consolidation after autologous stem cell transplantation in high-grade non-Hodgkin lymphoma. 34th EBMT Annual Meeting, Florence, Mar 30-Apr 2, 2008 (Bone Marrow Transplantation 2008, 41(s1)).

6. Musto P, Lunghi M, Di Renzo N, Mele G, Petrini M, Pietrantuono G, D'Auria F, Ferrara F, Leone G, VendittiA. 5-azacytidine for the treatment of acute myeloid leukemia: results in 45 patients from the italian patient named program. 13th EHA Congress, Copenhagen, June 12-15, 2008 (haematologica 2008, 93(s1)).

7. Maurillo M, Spagnoli A, Gozzini A, Rocco S, Filardi N, Specchia G, Galimberti S, Villani O, D'Auria F, Di Renzo N, D'Arco AM. Musto P. 5-azacytidine for the treatment of intermediate-2/high IPSS risk myelodysplastic syndromes: results in 83 patients from the italian patient named program. 13th EHA Congress, Copenhagen, June 12-15, 2008 (haematologica 2008, 93(s1)).

8. Musto P, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, D'Auria F, Zonno A, Zupa A, Bianchino G, Improta G, Grieco V, Digiovannantonio L, Feudale E, Lerose R, Pinto A, Ferrara F. A pilot study with rituximab, bortezomib and hyper-fractionated cyclophosphamide (RBC regimen) for the treatment of advanced mantle cell lymphoma in elderly patients. 13th EHA Congress, Copenhagen, June 12-15, 2008 (haematologica 2008, 93(s1)).

10. Musto P, Maurillo L, Spagnoli A, Gozzini A, Ciuffreda L, Palumbo G, Di Renzo N, Villani O, D'Auria F, D'Arco A, Galimberti S, Venditti A, Santini V. 5-azacytidine for the treatment of low/intermediate-1 IPSS risk myelodysplastic syndromes: results in 63 patients from the italian patient named program. 13th EHA Congress, Copenhagen, June 12-15, 2008 (haematologica 2008, 93(s1)).

11. Palumbo A, Falco P, Corradini P, Crippa C, Falcone A, Musto P, Pregno P, Luraschi A, Nozza A, Knight R, Boccadoro M, Petrucci MT, Melphalan, prednisone and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia/thrombocytopenia and time to event results. 13th EHA Congress, Copenhagen, June 12-15, 2008 (haematologica 2008, 93(s1)).

12. . Pozzi S, Marcheselli R, Sacchi S, Falorio S, Caparotti G, Natale D, Cuoghi A, Pitini V, Ponchio L, Spriano M, Musto P. Bisphosphonates (BP) related osteonecrosis of the jaw (ONJ): a long term follow up of a series of 35 cases observed by GISL. 13th EHA Congress, Copenhagen, June 12-15, 2008 (haematologica 2008, 93(s1)).

13. Boccadoro M, Bringhen S, Petrucci MT, Morandi S, Capaldi A, Rizzo M, Calabrese E, Omedè P, Musto P, Foà R, Palumbo A. Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, randomized phase III study. 13th EHA Congress, Copenhagen, June 12-15, 2008 (haematologica 2008, 93(s1)).

14. Pavone V, Del Casale C, Messa AR, Mele A, Dicembrino F, Caputo M, Ostuni A, Mettevier V, Pezzullo L, Musto P, Porretta F, Scalzulli P, Guarini A, Iacobazzi A, Angelucci E. Radioimmunotherapy and hemopoietic stem cell transplantation in patients with non-hodgkin's lymphoma (NHL): multicentre study of 43 pts. X Congress of the Italian Society of Experimental Hematology, Bari, Italy, September 24-26, 2008 (haematologica 2008, 93(s2)).

15. Voso MT, Santini V, Finelli C, Angelucci E, Cortellezzi A, Villani O, Petti MC, Gobbi M, Foa R, Amadori S, Liso V, Leone G. 5-azacytidine, valproic acid and all-trans retinoic acid in int-2/ high risk myelodysplastic syndromes: first results of the GIMEMA MDS0205 multicenter trial. X Congress of the Italian Society of Experimental Hematology, Bari, Italy, September 24-26, 2008 (haematologica 2008, 93(s2)).

16. Spagnoli A, Genuardi M, Lunghi m, Mianulli M, Pietrantuono G, D'Auria F, Venditti A, Santini V, Musto P. 5-Azacytidine for the treatment of acute myeloid leukemia: a retrospective, multicenter study of 55 patients. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

17. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Fili C, Palumbo G, Rocco S, Villani O, D'Auria F, Gaidano G, Leone G, Santini V. 5-azacytidine in 82 low/intermediate-1 IPSS risk myelodysplastic syndromes: results from the Italian Patint Named Program. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

18. Pietrantuono G, Guariglia R, Villani O, Martorelli MC, D'Auria F, Zonno A, Lerose R, Filardi N, Falcone A, Bringhen S, Palumbo A, Musto P. Bortezomib as front-line therapy in primary plasma cell leukemia. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

19. Oliva EN, Clissa C, Santini V, Poloni A, Liso V, Impera S, Cortelezzi A, Ghio R, Villani O, Aloe Spiriti MA. Quality of life assessment in patients affected by myelodysplastic syndromes. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

20. Guariglia R, Luminari S, De Renzo A, Iannitto E, Pozzi S, Pierri T, D'Amato L, Traficante A, Sacchi S, Musto P. A case-control study on the role of an antiviral treatment with interferon and ribavirin after conventional chemotherapy in diffuse large B-cell lymphomas with hepatitis C virus (HCV) infection. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

21. Voso MT, Santini V, Finelli C, Fioritoni G, Cortellezi A, Villani O, Buccisano F, Zini G, Fazi P, Gobbi M, Liso V, Leone G. 5-azacytidine, valproic acid and ALL-trans retinoic acid in INT-2/high risk myelodysplastic sindromes: results of the GIMEMA MDS0205 multicenter trial. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

22. Pavone V, Mele A, Rana A, Del Casale C, Greco G, Sibilla S, Varraso A, Vitolo U, Loseto G, Quarta G, Musto P, Caputo M, Ostuni A. Radioimmunotherapy (90Y-Zevalin®) combined with BEAM conditioning regimen and autologous stem cell transplantation for the treatment of non-hodgkin lymphoma: results of an italian multicenter study. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

23. .Cavo M, Testoni N, Terragna C, Marzocchi G, Zambello R, Nozzoli C, Masini l, Zamagni E, Tosi P, Ballanti S, Musto P, Grasso M, Pasini S, Ballerini F, Petrucci A, Baccarani M. Superior rate of complete response with up-front velcade-thalidomide-dexamethasone versus thalidomide-dexametasone in newly diagnosed multiple myeloma is not affected by adverse prognostic factors including high-risk cytogenetic abnormalities. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

24. Baldini L, Pulsoni A, Rossi G, Vitolo U, Morra E, Olivero B, Merli F, Musto P, Gamba E. Front-line chemo-immunotherapy rituximab-FC+rituximab mantenance in patients with untreated advanced stage non follicular lymphoma (INFL): preliminary results of a prospective study of the Intergruppo Italiano Linfomi and Roche (ML18324). 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

25. Palumbo A, Falco P, Gay F, Corradini P, Crippa C, Falcone A, Giuliani N, Musto P, Morabito F, Canepa L, Caltagirone S, Knight RD, Boccadoro M, Petrucci MT. Oral melphalan, prednisone and lenalidomide for newly diagnosed multiple myeloma patients: kinetics of neutropenia/thrombocytopenia and time to event results. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

26. Cavo M, Palumbo A, Bringhen S, Falcone A, Musto P, Ciceri F, Zambello R, Ciambelli F, Gherlinzoni F, D'Arco A, Martelli M, Tacchetti P, Baccarani M, Boccadoro M. A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

27. .Boccadoro M, Bringhen S, Petrucci MT, Liberati AM, Ria R, Nozza A, Caravita T, Calabrese E, Larocca A, Cavallo F, Musto P, Foà R, Palumbo A. Melphalan 220 mg/m2 (Mel220) versus melphalan 110 mg/m2 (Mel100) in newly diagnosed myleoma patients: a prospective, randomized phase III study. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).

28. Gentile M, Ciolli S, Mele G, Piro E, Pinotti G, Palmieri S, Callea V, Musto P, Bringhen S, Baldini L, Tosi P, Cavo M, Morabito F. Bortezomib (VEL) based regimens in multiple myeloma (MM) patients with renal impairment (RI): a preliminary retrospective italian multicenter study. 50th ASH Annual meeting, San Francisco, Dec 6-9, 2008 (blood 2008, 112 (11)).


29. Pedicini P., Fusco V., Manzo R., Rago V., Muto P.
Sub-Unità funzionali in serie e in parallelo: Effetto della Modifica del Frazionamento in Radioterapia. Radiazioni, Ricerca e Applicazioni. Volume XI n. 1, pag. 2-5. Aprile 2008.